SavedAdd your journal

Journals / Akademik Gastroenteroloji Dergisi / 2019 / Cilt: 18 - Sayı: 3

Ruptured hepatocellular carcinoma in a patient with chronic hepatitis C and a sustained viral response

Kalıcı viral yanıtı olan kronik hepatit C hastasında hepatosellüler kanser rüptürü

Şebnem KARASU
Fatih Esad TOPAL
Firdevs TOPAL
Sabiye AKBULUT
Pages
126–128
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KARASU, Ş., TOPAL, F. E., TOPAL, F., AKBULUT, S. (2022). Ruptured hepatocellular carcinoma in a patient with chronic hepatitis C and a sustained viral response. Akademik Gastroenteroloji Dergisi, Cilt: 18 - Sayı: 3, 126–128. https://ajindex.com/articles/648273

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Mangia A, Foster GR, Berg CP, et al; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin ther-apy in chronic hepatitis C: The real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43
  2. Furusyo N, Ogawa E, Nakamuta M, et al; Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepa-titis C. J Hepatol 2013;59:205-12
  3. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
  4. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic re-view, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12
  5. Alberti A, Piovesan S. Increased incidence of liver cancer after suc-cessful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int 2017;37:802-8